axitinib

axitinib is a small molecule tyrosine kinase inhibitor used as a second-line treatment for advanced renal cell carcinoma. It was developed by Pfizer and received approval from the U.S. Food and Drug Administration in 2012. The drug works by selectively inhibiting vascular endothelial growth factor receptors, which are critical for angiogenesis and tumor growth.

Medical uses

axitinib is indicated for the treatment of advanced renal cell carcinoma following failure of one prior systemic therapy. Its approval was based on the phase III AXIS trial, which demonstrated superior progression-free survival compared to sorafenib. The drug is typically administered orally on a continuous dosing schedule, and its use is often guided by dose titration based on individual tolerability and the absence of severe hypertension. Clinical studies, including research presented at the American Society of Clinical Oncology annual meetings, have also explored its potential in combination with immune checkpoint inhibitors like pembrolizumab for first-line treatment of renal cell carcinoma.

Adverse effects

Common adverse effects include diarrhea, hypertension, fatigue, decreased appetite, and nausea. More serious but less frequent events can involve arterial thromboembolic events, hemorrhage, gastrointestinal perforation, and reversible posterior leukoencephalopathy syndrome. The development of proteinuria and thyroid dysfunction are also monitored during treatment. Management strategies often involve supportive care, antihypertensive medications, and dose modifications or interruptions as outlined in the prescribing information from the European Medicines Agency.

Pharmacology

axitinib functions as a potent and selective inhibitor of vascular endothelial growth factor receptor subtypes VEGFR-1, VEGFR-2, and VEGFR-3. By blocking the ATP-binding site of these receptors, it inhibits signal transduction pathways mediated by VEGF, a key driver of tumor angiogenesis. The drug is metabolized primarily in the liver by the cytochrome P450 enzyme CYP3A4, with minor contributions from CYP1A2 and CYP2C19. Conjugation via UGT1A1 also occurs. Significant drug-drug interactions are possible with strong CYP3A4 inducers like rifampin or inhibitors like ketoconazole, necessitating dose adjustments.

History

The development of axitinib originated from research at Pfizer's laboratories, building upon earlier work with the tyrosine kinase inhibitor sunitinib. The pivotal AXIS trial compared axitinib to sorafenib in patients with previously treated renal cell carcinoma. Based on the positive results from this international study, the U.S. Food and Drug Administration granted approval in January 2012, followed by the European Medicines Agency later that year. Subsequent research efforts have focused on expanding its utility, including combination regimens investigated in collaboration with institutions like the National Cancer Institute.

Society and culture

axitinib is marketed under the brand name Inlyta by Pfizer. Its introduction provided an additional therapeutic option in the competitive landscape of renal cell carcinoma treatments, which includes agents like pazopanib and temsirolimus. The high cost of targeted therapy has sparked discussions on healthcare economics and drug pricing, often highlighted in forums such as the Journal of Clinical Oncology. Patient access programs have been established by Pfizer in various regions, and the drug's clinical impact is frequently analyzed in reviews by organizations like the National Comprehensive Cancer Network.

Category:Antineoplastic drugs Category:Tyrosine kinase inhibitors Category:Pfizer